In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Cancer Clinical Trials - COG-AREN1921
Protocol Summary
- Protocol No
- COG-AREN1921
- Principal Investigator
- Kerri Becktell
- Phase
- II
- Title
- Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
- Associated Disease(s)
-
Early Phase Trials (Phase I and II)
- Description (Summary)
- For Newly-diagnosed, diffuse anaplastic Wilms Tumor:
In this study, researchers want to find out if we can improve treatment for subjects (people who agree to take part in this study) in hopes of finding a better therapy to fight against the cancer you have, you will be given chemotherapy drugs and radiation therapy in this study. The overall goals of this study is to find out what effects, good and/or bad the regimens have on subjects.
- newly diagnosed diffuse anaplastic Wilms tumor, using a regimen known as UH-3
- standard-risk relapsed favorable histology Wilms Tumor, using a regimen known as UH-3
- high-risk or very high-risk relapsed favorable histology Wilms Tumor, using a known as Regimen ICE/Cyclo/Topo
In addition to the treatment goal, we would like to answer some biology research questions that might benefit future patients.
Regimen UH-3 is based on a similar treatment that was used in the last COG study for patients with high-risk kidney tumors, including diffuse anaplastic Wilms tumors. The initial results from the previous study appeared to show an improvement in outcome. This study is being performed to confirm those results. Compared to the treatment in the last study, Regimen UH-3 includes some supportive care additions and some re-ordering of drug cycles, to hopefully reduce side effects during treatment or in the future. Regimen UH-3 is considered experimental at this time for patients with diffuse anaplastic Wilms tumor and for patients with standard-risk relapsed favorable histology Wilms tumor.
The Cyclo/Topo regimen and the ICE regimen have been used in patients with relapsed Wilms tumors, but not usually as part of one treatment protocol. Previous studies showed that in general, the regimens were well tolerated in children with relapsed FHWT. This study examines if treating patients with both regimens remains tolerable and results in a better outcome for those with relapsed FHW.
- Participating Institutions
- Childrens Hospital of Wisconsin
- ClinicalTrials.gov
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
